Research Article
Effect of Donepezil on Sleep and Activity in Alzheimer's Disease: Actigraphic and Polysomnographic Assessment
Tsuyoshi Miyaoka1*, Junya Tsukada2, Soichi Mizuno1, Ryoji Nishimura2, Yasushi Inami3 and Jun Horiguchi1
1Department of Psychiatry, Shimane University School of Medicine, Izumo, Japan
2Department of Psychiatry, Fukuoka University School of Medicine, Fukuoka University, FukuoKa, Japan
3Ehime Rosai Hospital, Imabari, Japan
- Corresponding Author:
- Tsuyoshi Miyaoka
Department of Psychiatry
Shimane University School of Medicine
89-1 Enyacho, Izumo 693-8501, Japan
Tel: 81-853-20-2260
E-mail: miyanyan@med.shimane-u.ac.jp
Received date: January 16, 2014; Accepted date: September 25, 2014; Published date: October 03, 2014
Citation: Miyaoka T, Tsukada J, Mizuno S, Nishimura R, Inami Y et al. (2014) Effect of Donepezil on Sleep and Activity in Alzheimer’s Disease: Actigraphic and Polysomnographic Assessment. J Alzheimers Dis Parkinsonism 4:157. doi: 10.4172/2161-0460.1000157
Copyright: © 2014 Miyaoka T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Aim: To examine the effect of on sleep and daily activity in patients with Alzheimer-type dementia (ATD) using polysomnography and actigraphy. Methods: Ten patients with mild to moderate ATD (mean age: 76 ± 6.2 years) were studied. The Alzheimer’s disease Assessment Scale-cognitive component-Japanese version (ADAS-Jcog),polysomnography, and 7-day recording of actigraphy data were performed. Following this baseline assessment, donepezil (5 mg daily) was administered every morning for 6 weeks, after which the ADAS-Jcog, polysomnography, and actigraphy were repeated. Results: After 6 weeks of treatment with donepezil, daily activity was significantly increased (276.2 ± 89.2 vs. 326.1 ± 98.6; p < 0.05). Similarly, rapid eye movement (REM) sleep (11.3 ± 4.1 vs. 17.1 ± 4.4; p<0.01) and sleep efficiency (76.2 ± 16.3 vs. 82.8 ± 10.6; p<0.05) were significantly increased compared with baseline. Although the ADAS-Jcog score did not decrease significantly (18.5 ± 6.8 vs. 15.9 ± 7.3; P= 0.054), there was a significant positive correlation between the decrease of this score and the increase of daily activity (r= 0.2137, p= 0.4809). Conclusions: An increase of daily activity and cognition were induced by donepezil treatment in patients with ATD, possibly based on improvement of the sleep structure. Trial Registration: Controlled-trials. Com Identifier: UMIN000005018
